Qurient Co., Ltd. (KOSDAQ:115180)

Market Cap	354.87B
Revenue (ttm)	9.18B
Net Income (ttm)	-23.57B
Shares Out	35.56M
EPS (ttm)	-752.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	142,380
Average Volume	218,974
Open	10,370
Previous Close	10,360
Day's Range	9,960 - 10,380
52-Week Range	3,200 - 10,510
Beta	0.69
RSI	61.23
Earnings Date	May 13, 2025

About Qurient

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 115180

Financial Performance

In 2024, Qurient's revenue was 9.18 billion, an increase of 1.64% compared to the previous year's 9.03 billion. Losses were -23.57 billion, 11.6% more than in 2023.